A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

B A C K G R O U N D: Treatment for TB is lengthy and toxic, and new regimens are needed. M E T H O D S: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ)...

Full description

Bibliographic Details
Main Authors:	Amukoye, E. (Author), Balanag, V. (Author), Ban, A.Y.L (Author), Bateson, A.L.C (Author), Betteridge, M.C (Author), Brumskine, W. (Author), Caoili, J. (Author), Cevik, M. (Author), Chaisson, R.E (Author), Conradie, F. (Author), Crook, A.M (Author), Dawson, R. (Author), del Parigi, A. (Author), Diacon, A. (Author), Everitt, D.E (Author), Fabiane, S.M (Author), Gillespie, S.H (Author), Hunt, R. (Author), Ismail, A.I (Author), Lalloo, U. (Author), Lombard, L. (Author), Louw, C. (Author), Malahleha, M. (Author), McHugh, T.D (Author), Mendel, C.M (Author), Mhimbira, F. (Author), Moodliar, R.N (Author), Nduba, V. (Author), Nunn, A.J (Author), Sabi, I. (Author), Sebe, M.A (Author), Selepe, R.A.P (Author), Spigelman, M. (Author), Staples, S. (Author), Swindells, S. (Author), Tweed, C.D (Author), van Niekerk, C.H (Author), Variava, E. (Author), Wills, G.H (Author)
Format:	Article
Language:	English
Published:	International Union Against Tuberculosis and Lung Disease 2021
Series:	International Journal of Tuberculosis and Lung Disease
Subjects:	adult aged alanine aminotransferase Antitubercular Agents arthralgia Article aspartate aminotransferase clinical protocol combination drug therapy controlled study drug efficacy Drug resistance Drug Therapy, Combination drug withdrawal ethambutol female human Humans hypertransaminasemia hyperuricemia intention to treat analysis isoniazid K E Y W O R D S: tuberculosis lung tuberculosis major clinical study male moxifloxacin Moxifloxacin multicenter study nitroimidazole derivative Nitroimidazoles open study outcome assessment patient selection phase 3 clinical trial pretomanid pyrazinamide Pyrazinamide randomized controlled trial relapse rifampicin TB treatment TB-HIV thorax radiography treatment duration treatment failure treatment outcome Treatment Outcome treatment response tuberculostatic agent
Online Access:	View Fulltext in Publisher View in Scopus

by Amukoye, E, Balanag, V, Ban, AYL, Bateson, ALC, Betteridge, MC, Brumskine, W, Caoili, J, Cevik, M, Chaisson, RE, Conradie, F, Crook, AM, Dawson, R, del Parigi, A, Diacon, A, Everitt, DE, Fabiane, SM, Gillespie, SH, Hunt, R, Ismail, AI, Lalloo, U, Lombard, L, Louw, C, Malahleha, M, McHugh, TD, Mendel, CM, Mhimbira, F, Moodliar, RN, Nduba, V, Nunn, AJ, Sabi, I, Sebe, MA, Selepe, RAP, Spigelman, M, Staples, S, Swindells, S, Tweed, CD, van Niekerk, CH, Variava, E, Wills, GH
Published 2021

View Fulltext in Publisher

Article

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Similar Items